Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license
By Eric SagonowskyFeb 24, 2023"
https://www.fiercepharma.com/pharma/moderna-pays-us-government-400m-catch-payment-under-new-covid-19-vaccine-license
Wut da problem is?
Good to see you, JA3. Your link just took me a Linked-In sign in page. I don't have a Linked-In account.
It made sense to me, as I said in a previous post, to transfer the IP rights to Taran to safeguard the IP in the event that the bankruptcy court judge converted the case to CH7, in which case the IP would have been included in the sale.
Did Humanigen have entitlement to sells revenue earned by our Korean partner, simply because we owned the IP? No.
Nor would Taran have entitlement to sells revenue earned by Humanigen.
We just haven't see the details yet regarding licensing, or a possible merger. What we DO know is that Taran did not submit a tender offer to buy Humanigen, which is the only way Taran could claim sells revenue. But again, as Asset Purchase Agreement is not a buy-out.
Well, first of all, I don't see a revenue stream for Taran. It will be Humanigen's revenue. And did you see Durrant resign as Humanigen's CEO? I didn't.
The in-process structural change has not diminished Humanigen's capacity to execute their business plan. I'm not worried at all. In act, I'm excited to see how all the pieces will fit together.
The bankruptcy judge did not share your pessimistic view.
It's a very exciting time for us, Jim!
In regards to my oft-wondered-about covid pneumonia reinfection rate in lenz-treated patients, which I think could be an absolute game-changer for Humanigen's lenzilumab, I learned last night that I may again have to re-phrase my question, and likely have to ask more than just one question. But just to get started, let me ask the following.
In patients diagnosed with covid pneumonia, and treated with lenzilumab, what is the recurrence rate of those patients presenting with SARS-CoV-2 nucleocapsid proteins after treatment? (I'll have to pin this post to remember how to ask that question).
As my question was originally phrased, I didn't know better than to exclude subsequent presentations of covid found in spike proteins. The studies I reviewed last night demonstrate that covid in the spike proteins has no relation to how well lenz prevents future infections. Rather, as I read the studies I will link, covid found in spike proteins is mRNA vaccine-induced. So lenz-treated patients who subsequently present with covid spike proteins, have no bearing on the efficacy of lenz.
Attached is an autopsy report of a 76 year old man, which was used as a case study. The patient had no history of covid, but the pathologist found covid spike proteins leading to the heart and brain. It's a fascinating study which, along with a different, un-related discussion concerning San Vincente in the Darian Pass, kept me up all night reviewing.
The presentation gets off to what might be perceived as a slow start, but don't fast forward past the 11 minute mark, of the 28 minute video.
Interesting niche. But I don't see anything about production turnaround, and it appears that their CAR-T is designed to enhance mitigation of CCR-9. I think Gracell's 24 hour turnaround for CAR-T is a much better, even revolutionary, alternative, which I hope that lenz is a part of making that happen.
I see that they also provide CRISPR services. I think that lenz was developed with that gene-editing technology. But even so, I'm not comfortable with it, generally. And I see that GenScript also provides mRNA solutions, and I am becoming increasingly wary of that.
Lots and lots of potential with those technologies, but way too much opportunity for abuse of those capabilities.
https://www.genscript.com/?src=google&utm_source=google&utm_medium=cpc&utm_campaign=GenScript-ECPC_NA&jiraid=12194&gad_source=1&gclid=EAIaIQobChMIzsnPnL_ihAMVGy7UAR2UUQsxEAAYASAAEgJy3vD_BwE
Do you have a minute? Do you have 51 minutes?
I had never heard of Sharyl Attkisson, or her "Full Measure" weekly broadcast program, but I was fortunate enough to have just finished watching her program on "The Covid Clots," and I highly recommend that you watch it. It so happens that I am scheduled for an exam by my vascular surgeon on Friday, because it has been a year since he did the angioplasty/atherectomy on my leg artery. And I'm curious to see if he is familiar with the information I just learned about covid clots.
You brought this issue up last month, Jim
February 14, 2024
Isn't HGEN bankrupt? how do HGEN share holders have any chance at success? I was under impression that assets would be sold off and HGEN stock worth nothing now.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173844576
and I gave you my thoughts on this subject at that time
02/14/24
Hi, Jim,
Welcome to the room, and to Ihub.
If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.
But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.
Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.
https://moxreports.com/kbio-infinity-squeeze/
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.
https://investorshub.advfn.com/boards/replies.aspx?msg=173844576
What right does Taran have to recall the loaned shares? Did they loan any of those shares? What clinical trial relationships does Taran have with Humanigen's partners, working on bringing lenz to market for CMML, or aGvHD, or Covid, or for any of Sanofi's oncology or asthma indications? Taran's CEO Durrant could make Humanigen's CEO Durrant sign a licensing agreement, which he may have done already, if that would alleviate your concern.
But, Taran did not buy Humanigen. I think Humanigen remains on track with all of their on-going work, and the pending results of all that work are what shareholders have to look forward to accomplishing. If you think I'm missing something, maybe I am, in which case please inform me of what that is.
Is the Sanofi spin-off of their healthcare division designed to partner with Humanigen on the asthma market, and more?
According to Humanigen's Featured Presentation, "...historical clinical results could provide basis for global partnering discussions."
asthma mentioned on five slides in the chart deck
https://ir.humanigen.com/English/events-and-presentations/default.aspx
Does Sanofi think that lenz could do better than their Regeneron partner, using Dupixent? Or is Sanofi looking to expand their supply chain?
https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-fda-approved-first-and-only-treatment
There are worse problems to have than trying to figure out what will be the most valuable entity for Humanigen shareholders 🙂. You make some good points and I can understand your enthusiasm, which I share, for our success in Australia.
But, if the loaned shares are recalled, chances are it will be with news, and Humanigen's value could skyrocket well beyond the value of their subsidiaries or Taran, if that news is related to covid prevention/treatment authorization. And in that regard, I now see news from the UK Ministers accusing the Health Secretary, "...of withholding data that could link the Covid vaccine to excess deaths, and criticised a “wall of silence” on the topic.
A cross-party group has written to Victoria Atkins to sound alarm about the “growing public and professional concerns” at the UK’s rates of excess deaths since 2020."
https://www.yahoo.com/news/health-secretary-urged-release-data-181513423.html
I'm disappointed that the UK regulators did not act independently and much earlier to approve lenz for covid. So I'm glad to see pressure building on them in this regard. I think a study of lenz patients could actually show "decreased deaths" and negligible (or at least show a statistically significant lower level) of covid pneumonia reinfections.
You can never be sure how a bankruptcy court judge is going to rule, even with guys like Barliant (?) helping the company through the process. I appeared once in a corporate bankruptcy case, where the issue concerned naked shorting. The company was being naked shorted tens of millions of shares everyday, even though they were on the Failure-to-Deliver (FTD) list. The judge told me that he thought I (shareholders) had a case. But he couldn't see how naked shorting negatively impacted the issuer. I was dumb-founded, and I mean literally.
So, I can see how transferring intellectual property rights to Taran could have been a safeguard, pending how the judge ruled.
Beyond that, in my opinion, it has made a lot of sense to use Dale's entities as we have, broadly, as what I call our financing arm. I hope, going forward, that we continue to segregate our financing and operational activities, in the manner that we have. But I have to think that the value of Humanigen's shares is a reflection of the value of our intellectual property, and I expect that issue will be addressed as you mentioned, either by way of exclusive licensing, or with a potential merger through subsidiaries of Humanigen and Taran.
"COVID-19 remains a danger, especially to older people and those with underlying medical conditions. There are still more than 20,000 hospitalizations and more than 2,000 deaths each week due to the coronavirus, according to the CDC. And people 65 and older have the highest hospitalization and death rates."
https://www.yahoo.com/news/older-us-adults-another-covid-191550624.html
No, thanks. I'll have lenz, please.
You're right, eb.
And there's so much going on. Today, for example, Baudax filed a CH11. Will this give us the opportunity to bid on Tera-Immune?
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1780097/000119312524049000/d800225d8k.htm
And Sanofi's notice of appointing 3 Independent Directors yesterday, having already announced plans to spin-off their healthcare business, suggests preparations to ready the spin-off for Nasdaq listing.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412dex993.htm
And as Preciouslife1's article informed us today, "Novavax expects full-year 2024 revenue to come in between $800 million and $1 billion. That forecast reflects an expected $500 million to $600 million in revenue from advanced purchase agreements and $300 million to $400 million from commercial market product sales, royalties and other revenue from the company’s “partner-related activity.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173936647
"What will be left in Humanigen ?"
If our float is as once reported, 229M shares, I believe that 110M (~90% of our OS) of those shares could be owned by Humanigen. That might be a whole lot of nothing, at a share price of $0.0001, or so, and no regulatory authorizations or approvals for lenz, and no customer demand.
But that could change instantly with news.
Pick a share price, if the brokerages are forced to buy-in shares, whether from a recall of the loaned shares, or a merger, and remember...the company owns most of the shares. So I'm hoping to sell some shares for about $200, especially if we're still on the Expert Market.
But, THERE'S SO MUCH POTENTIAL, that even if I can't sell at my target price, just our fundamental price could be in the $60 range ($8B, for example.) market cap, if we can get into the covid prevention market with the Novavax vaccine, and/or regulatory approval for CMML, not to mention a PRV, Humanigen could end up with a boat load of cash.
Hello, InfinitePhoenix4. Welcome to the room, and thank you for posting your first Ihub message here. I appreciate the thought you put into it.
I think it is very likely that lenz could receive it's first regulatory approval in Australia, to treat CMML. It's also possible that a Priority Review Voucher in the range of ~$100M could be awarded with that approval.
But Taran didn't buy Humanigen. Taran bought the intellectual property rights. Do you agree, because I don't think you do? Let's start there, if you want.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
I haven't given the document the full study it deserves, because I have total confidence in management. I am as confident in Dale's stewardship of Humanigen's shares, as I am in Durrant's purchase of the intellectual property rights. Besides, I think we will see a merger, anyway. So I don't foresee value being left behind, once the share structure and the intellectual property rights are rejoined (joined), by some means.
I hope this all becomes moot, but even more so, I also hope to see the recall of the loaned shares, in short order. But I do agree that our value lies in the intellectual property, and have said that, "To be honest, I think it would take a lot more study for me to feel that I have confidence in making a deduction about HOW these guys have navigated during this bankruptcy." I'm looking forward to the completion of our restructuring.
We're not at our destination.
I don't understand you guys. The bankruptcy was brilliantly designed and executed, and the CH11 was successfully achieved. Between the rights Humanigen retained by way of the Excluded Assets, and also having a foreign subsidiary unencumbered to maneuver, I don't know what we can't do, that needs to be done, as the restructuring is completed.
Company of interest Sanofi, who appears to have long ago converted their common shares of Kalobios into preferred shares, today released a 6-K regarding several of their mabs and clinical trials. Also included was a press release concerning the appointment of three new Independent Directors. I wonder if the new Independent Directors are being appointed to gain Nasdaq compliance in the US, ahead of the spin-off of their healthcare division.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412d6k.htm
With Gracell having completed becoming a subsidiary of AstraZeneca, and deregistering their stock on Nasdaq, I'm going to replace them with Sanofi (SNY) as one of the stocks I watch for SEC filings.
Sanofi is showing several recent beneficial ownership filings.
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001121404&owner=exclude
I don't think you're giving full consideration to both Humanigen's and Taran's blank-slate foreign subsidiaries, and to how they may be used to capitalize on the use of the Excluded Assets recognized by the bankruptcy court judge. And that is totally understandable, and intended. I think that same lack of understanding is shared by certain of the unsecured creditors, who should appreciate management's ongoing effort which is, in part, on their behalf, in my opinion.
I don't see any real change, or impediments, to the accomplishment of management's goals. In fact, I see just the opposite, as management is free to proceed without the degree of financial constraints they have been under.
The fact is that the bankruptcy court judge did not convert the case from CH11 to CH7.
"Motions to convert to Chapter 7 for cause may be granted if the court examines the facts of the case and finds one or more of the following:
The debtor has no profitable core business around which to structure a reorganization.
The debtor cannot or will not formulate a reasonable reorganization plan.
The debtor’s financial picture indicates little or no ability to generate income and as such there is little reasonable likelihood of rehabilitation.
The debtor’s business is suffering continuing losses by remaining in operation, which may be shown by its negative cash flow during Chapter 11 and/or its inability to pay ordinary costs of business such as insurance, taxes and interest.
The debtor has failed to comply with the court’s filing and reporting requirements, thus showing that it has not exercised the due diligence expected of a Chapter 11 debtor.
The debtor is not using Chapter 11 for a legitimate reorganization effort or is otherwise not acting in good faith."
https://www.bankruptcypower.com/blog/when-can-a-court-convert-your-chapter-11-reorganization-to-a-chapter-7/
The judge found NONE of the above. Durrant, who knows more about our pathway than anyone, except Dale, is investing millions more into lenzilumab and our product pipeline. I think the AstraZeneca/Gracell/and Grey Wolf merger sub transactions, may represent a structural template of what we may see. Regardless, we are Humanigen shareholders, and we will be the financial beneficiaries of a recall of the loaned HGEN shares. As I showed in the historical record of the first recall of our loaned shares, business fundamentals are meaningless, if brokerages are forced into buying-in their customers' short position by a recall of the loaned shares.
With one major exception, I think management planned for this potential outcome from the start, and designed their share structure to capitalize on this eventuality, as they had to do to protect the company and their shareholders. The unplanned exception was the covid pandemic, which raised the risk/reward ratio exponentially, and we are about to experience the "reward" part of that ratio.
Durrant remains in control of the product pipeline. I don't think the Taran CEO is going to do anything that the HGEN CEO doesn't want to do, that is, assuming the two companies remain distinct entities, which I doubt they will.
Sanofi hasn't garnered much attention here. I did, however, previously note that they appear to have been one of the beneficiaries of Humanigen's Original Issuance of Shares (OIS). As I recall, I think their stake was for less than 5% of our shares, and did not require the filing of a beneficial ownership statement. I mention them again because of their announced intention to spin-off their healthcare division, resulting in a separate listing later this year. So, it's a timing consideration regarding an entity that may have a long-standing knowledge of our objectives and capabilities that prompts me to mention them again.
But, something else that's been mentioned lately is a privately held pharmaceutical company, such as we were engaged with at one time with the objective of establishing a business combination. My thought at the time we announced that objective was that PCI Pharma may have been our prospective partner, and that may still be true. But another candidate for a business combination has developed. I'm referring to AstraZeneca. I think lenz would be compatible with their Covishield adenovirus vaccine. Another consideration would be that Gracell has now become a subsidiary of AstraZeneca.
"SAN DIEGO and SUZHOU, China and SHANGHAI, China, February 22, 2024 -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent." The mechanics of this transaction fascinate me, too, if Humanigen uses one of their foreign subsidiaries, or Taran uses one of their subsidiaries, as a merger sub in bringing AZ and HGEN together.
https://www.sec.gov/Archives/edgar/data/1826492/000110465924026350/tm246846d1_ex99-1.htm
I continue to think, however, that Novavax offers the most synergy with Humanigen. I did not think that Novavax would survive without using lenz to enhance their prototype Covid vaccine. And they may not. But recent news is developing on two fronts that could have a profound impact on Humanigen's lenz for covid, AstraZeneca, Novavax, and Humanigen could all see dramatic increases in demand for their non-mRNA covid products if, for example, the Department of Defense, through our BARDA or CRADA agreements, has asked Humanigen for a stockpile of lenz (even if the House is also focused on Russia's possible deployment of nuclear missiles in outer space).
I have long said that I think lenz has the potential to stop, or to have stopped, millions of preventable covid deaths. Tough to do, if the Johns Hopkins covid data was correct, when they stopped collecting data in March of 2023, when they were reporting 6.9M covid deaths.
https://coronavirus.jhu.edu/map.html
But I am now seeing several sources, including Bret Weinstein and Steve Kirsch, using VAERS data and time modulated cohort analyses, report that the actual covid death toll in vaccinated patients has been in the range of 13M-17M people. Of course, factcheck.org disputes that.
🚨 Estimated 13 - 17 million deaths from the COVID vaccine, "It's over 13 million people easily."
— Tucker Carlson Network (@TCNetwork) February 23, 2024
Watch @TuckerCarlson and @stkirsch discuss the estimated death toll from the COVID vaccine: pic.twitter.com/c1u7lwPfvn
"Still in progress are developments regarding Baudax/Tera-Immune, and Humanigen/Taran."
Sometimes, the people who got you where you are, are not the people who will take you where you're going. But sometimes, they are the same. "ND" announced three days ago that they are looking for acquisitions.
I wish I had some information about the resolution of Dale's Appeal. Common sense tells me that he prevailed, since it appears that things appear to be progressing with Taran. But that Appeal could have significance in regards to "ND" developments. "Timing" is the only reason I hint at this, along with history.
"I track SEC filings everyday for Humanigen, Baudax, Gracell, and Novavax." Progress report.
Now, Form 25-NSE filings have been made for three of the above companies, to remove their stock from listing on the Nasdaq.
We know that news has now been reported for Novavax and Gracell.
Novavax:
"Novavax settles dispute with international vaccine group Gavi
By Michael Erman
February 22, 20249:43 AM CST
Shares of the company rose 23.2% to $4.91 on Thursday.
Its stock has dropped nearly 60% since the company last year raised doubts about its ability to remain in business. Nearly half of Novavax's free float shares were in short position, as of Jan. 31."
https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-settles-dispute-with-international-vaccine-group-gavi-2024-02-22/
Noteworthy are the recent beneficial ownership filings.
https://www.sec.gov/cgi-bin/browse-edgar?company=novavax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1000694/000110465924026225/tm246954d1_8k.htm
Gracell:
"SAN DIEGO and SUZHOU, China and SHANGHAI, China, February 22, 2024 -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent."
https://www.sec.gov/Archives/edgar/data/1826492/000110465924026350/tm246846d1_ex99-1.htm
And again, we see a number of recently filed beneficial ownership statements for Gracell.
https://www.sec.gov/cgi-bin/browse-edgar?company=gracell&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
I think the efficacy of both Gracell's CAR-T, and the Novavax prototype vaccine, may prove to have been greatly enhanced by using lenzilumab in those applications. We haven't seen evidence of that yet. However, we certainly saw game-changing enhancement of CMML treatment using lenz in the PREACH-M study.
"MedicalResearch.com: What are the next steps in this study?
Response: The PREACH-M trial is a phase 2/3 trial. We plan to unveil new data showing comprehensive clinical responses according to established criteria, somatic mutation frequencies and bone marrow plasma inflammatory cytokine levels at international meetings later this year.
Humanigen and SAHMRI are assessing regulatory pathways that may enable early results to support a regulatory submission and potential provisional registration or approval by the Therapeutic Goods Administration in Australia. We are also considering opening up PREACH-M, or a similar study in other countries such as the UK and the US, subject to resourcing and Humanigen’s corporate strategy."
https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/#:~:text=The%20preliminary%20results%20from%20the,cells%20with%20RAS%2Dpathway%20mutations.
Still in progress are developments regarding Baudax/Tera-Immune, and Humanigen/Taran.
Proud of yourself?
Is Durrant getting an even bigger bang for his drug development bucks? I like the fact that Dale sold his Baudax shares, but that Intracoastal bought shares in the same time period. Will this present an opportunity for us regarding Tera-Immune?
Much more importantly, I see where Novavax announced today that they have entered into a Settlement Agreement with Gavi, regarding an Advanced Purchase Agreement.
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1000694/000110465924026225/tm246954d1_8k.htm
https://www.cnbc.com/2024/02/22/novavax-to-settle-gavi-arbitration-over-canceled-covid-shot-purchase.html
The event that I am most looking forward to is the recall of our loaned shares, which may give me a brief moment to sell shares into a short squeeze.
But, the potential partnership that I am most looking forward to would be a stock-for-stock transaction with Novavax in a merger or business combination. I think that could lead to sustained annual revenue of over $67 per share, giving us a Market Cap in the $8B range.
The Gavi settlement greatly improves the outlook for Novavax to survive, and I hope it will prove another of the requirements for Humanigen to proceed with this venture (the first requirement was to significantly reduce R&D expense, which they have done). With the current institutional interest in Novavax, I am very excited about a possible pending announcement about a partnership with us.
It might be worth watching this development as it may relate to us. Too early to tell right now.
"Sanofi's consumer healthcare division draws private equity interest for spin-off. JPMorgan values it at $20B. Separate listing possible in Q4 2024. Other firms eyeing the unit."
Management focused on diverse patient enrollment in the LIVE-AIR trial, and discovered an 8-fold improvement in treatment outcomes for Black and African-American patients. The NIH ignored that astounding find.
And now, as we have seen previously from NIH studies, we have this:
"Monday, February 19, 2024
275 million new genetic variants identified in NIH precision medicine data
Study details the unprecedented scale, diversity, and power of the All of Us Research Program...
While more research is needed before these findings can be used to tailor genetic testing recommendations for specific populations, researchers believe the difference in the number of these variants may be influenced by past studies’ limited diversity and their disease-focused approach to participant enrollment, rather than a difference in the prevalence of the variants."
https://www.nih.gov/news-events/news-releases/275-million-new-genetic-variants-identified-nih-precision-medicine-data
Hypocrites. They report their findings, but don't take steps to implement them.
I hope they have success with implementing genetic tests for diverse populations, but authorizing lenz could have a huge impact on diverse covid populations NOW.
https://www.nih.gov/news-events/news-releases/researchers-optimize-genetic-tests-diverse-populations-tackle-health-disparities
Preventable deaths, in our case, are an effect of the government's abuse of discretionary authority, which I was fighting even before my wife's cancer (and covid) diagnoses, and the skin and tissue damage that she suffered from the radiation, which led to a need for wound care.
Preventable covid deaths continue on a daily basis in the US and around the world, and as long as that continues, I will continue to support management's efforts to get lenz authorized or approved.
A thief may demand your money or your life. It takes a special kind of low for government agencies to cause the loss of both.
Watching as this continues to evolve.
I've got multiple motivations for wanting lenz to succeed. As a shareholder, and like all of us here, I am financially motivated to see us succeed. But I also feel compelled to focus every bit of light that I can, on the government's abuse of their discretionary authority. This doesn't just apply to the SEC's failure to regulate our equity market, but also applies for the deadly abuse of discretionary authority by Regulatory agencies such as NIAID, the NIH, and the FDA. In addition, once my wife's wound care requirements progressed beyond the point that the visiting nurse could control the wound's progression, my wife had to return to the skilled nursing center in February of 2020. where she remained until her death in Nov 2020, exactly the period that covid arrived in the US, and stretched our health care system to the breaking point. As study after study began to appear thereafter, I knew lenz could have, at least, greatly improved the quality of her remaining life, and I will remain committed to seeing lenz authorized and approved around the world. I can't stand the thought that patients' families are suffering the preventable loss of their loved one's life.
So I remain hopeful to see lenz approved, and I feel confident that management has taken a steadfast, disciplined, methodical approach, to make that happen, against all Big Pharma and Regulatory odds.
I look forward to seeing how management may use their hollowed-out foreign subsidiary. Will this prove to be a merger entity for Taran, as I began talking about over the last month, or so?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173637775
To be honest, I think it would take a lot more study for me to feel that I have confidence in making a deduction about HOW these guys have navigated during this bankruptcy. I can't wait to learn as much as I can.
But I have supreme confidence that management has provided the essential ingredients for our explosive success, to include the legal framework, product safety and efficacy, pending corporate structure, regulatory approval, and market penetration. Oh, and that little thing called the recall of our loaned shares. Maybe in the remainder of the week, and hopefully in just one more day, we will finally learn.
There are Excluded Assets in the sale.
"1.2 Excluded Assets. Notwithstanding anything to the contrary in this Agreement, in
no event shall Seller sell, transfer, assign, convey or deliver, or be deemed to sell, transfer, assign,
convey or deliver, and Seller shall retain, all right, title and interest to, in and under any assets
other than the Acquired Assets (collectively, the “Excluded Assets”) including such right, title or
interest in the following:
(g) except with respect to the Foreign Subsidiary, all shares of capital stock,
limited liability company interests, or other equity interests of Seller and each of its respective
Subsidiaries or securities convertible into, exchangeable or exercisable for any such shares of
capital stock, limited liability company interests, or other equity interests;"
pp 45-46/95
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
So I disagree with TwongStocks saying that Taran will not be acquiring any equity of HGENQ. I think the above says, in effect, that Taran WILL be acquiring HGEN shares held by Dale's entities.
I think this is saying that shares in HGEN stock are excluded from the the sale to Taran, EXCEPT for those shares held by Dale's entities. I could be wrong, this is a lot of information to process in a compressed time. But it is my best interpretation of what this means. I just hope that the conclusion of the bankruptcy brings about the recall of the loaned shares, and perhaps a bit of additional news.
I think the brokerages could buy-in their customers who are short, without needing current filings, based just on a recall of the loaned shares. The thing is, for me, I just think we are about to see movement on multiple fronts, including an uplisting. So we may, or may not, need news to get the most out of the recall or the uplisting. The delinquent filings could already be completed. We don't have enough details to be able to draw conclusions now. I wouldn't even be speculating at all, if it wasn't for a legitimate concern about the Asset Purchase Agreement. Going that route instead of a buyout never caused me any concern, but I can understand that others can be concerned about that.
I still think we'll have news about a partnership with Novavax, and I still think that an $8B market cap for Humanigen is feasible. And to go even further out on a limb, I still think that Astra-Zeneca could be looking at using lenz with their Covishield vaccine, not just with their and Gracell's CAR-T.
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html
https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine
sosjtb,
The question is, what is Humanigen's most valuable asset? I think, for the very near term, it is having a float of 229M shares, which is 110M more shares in the market, than the company has issued. These shares are controlled by Dale's entities, which I view as our financing arm, and as we know, these shares are currently virtually worthless.
But the Asset Purchase Agreement, versus a Buy-Out, does not represent Durrant abandoning those shares, which have been loaned out. They are significantly beneficially owned by Humanigen. I think Humanigen owns 110M of those shares. So it may be that the recall of the loaned shares may be announced by Dale, if not Durrant.
Once, or as, the loaned shares have been recalled, I think we could announce a stock-for-stock merger or business consolidation with Novavax. That will then become our most valuable asset, as it could result in billions of annual revenue dollars, assuming that lenz was integrated into the Novavax prototype vaccine.
I feel like you're calling cadence, and have just ordered the first row of troops to execute a "to the rear, march" command. I certainly feel that positing what I have just sequenced is a dramatic change in course.
The share structure remains intact. You have 4.1M shares of HGENQ now, and you'll still have 4.1M shares of HGEN once the bankruptcy has closed (which will drop the Q suffix).
Yes, the deadline to get this wrapped up is Tuesday.
Thank you for that, bencozey. I have followed this company since 2015, when they were known as Kalobios, and issued the first recall of their loaned shares. A few weeks after they became Humanigen in 2017, I bought and have maintained a small position here. In 2022 and 2023, I discontinued selling shares, but continued to add as I could. So I'm really looking forward to the recall of their loaned shares, and seeing my open sell orders filled.
One of the things I'm really going to look forward to will be the financial press interviews of Durrant after what will be our historic short squeeze. I'm sure the press will want to know about the reasons for our delayed regulatory approval, which could have saved millions of lives worldwide if approved earlier, and could have greatly alleviated the trillions of dollars in damage to the world's economies and societies. I'm also sure that the press will want to know how management acquired about a 90% control of the company, and how and why the company acquired that ownership.
The answers could shine a lot of light on the government's deadly abuse of their discretionary authority, and their willful/criminal negligence, in service to their Big Pharma sponsors.